The purpose of this study is to examine the regulation of blood pressure and fluid and electrolyte homeostasis in mice over-expressing Angiotensin II (Ang-II) in the brain, and to determine if there are significant physiologic differences in Ang-II production in neurons or glia. Therefore, we generated and characterized transgenic mice over-expressing human renin (hREN) under the control of the GFAP promoter (GFAP-hREN) and Synapsin-I promoter (SYN-hREN) and bred them with mice expressing human angiotensinogen (hAGT) under the control of the same promoters (GFAP-hAGT and SYN-hAGT). Both GFAP-hREN and SYN-hREN mice exhibited highest hREN mRNA expression in the brain and had undetectable levels of hREN protein in the systemic circulation. In the brain of GFAP-hREN and SYN-hREN mice, hREN protein was observed almost exclusively in astrocytes and neurons, respectively. Transgenic mice overexpressing both hREN and hAGT transgenes in either glia or neurons were moderately hypertensive.
Introduction
The peptide angiotensin II (Ang-II) is the main circulating effector hormone of the reninangiotensin system (RAS), and is able to act not only on peripheral vascular structures, but also on the central nervous system (CNS) to increase blood pressure (BP) (1) . Substantial evidence has accumulated that Ang-II has actions on the CNS including increasing sympathetic outflow, arginine vasopressin (AVP) release, water intake, and salt appetite (2) . Existence of a local RAS in the CNS has been suggested since all components of this system have been reported in the brain. In addition, several lines of evidence point to a contribution of an overactive brain RAS to the hypertensive state in spontaneously hypertensive rats, DOCA-salt hypertensive rats, Dahl-salt sensitive rats, and renal hypertensive rats (3) (4) (5) (6) .
Despite numerous studies demonstrating the important cardiovascular effects of Ang-II or Ang-II receptor antagonists injected into the brain, it remains unclear whether RAS components synthesized in the brain, in particular renin and angiotensinogen (AGT), have an important role in the local synthesis of Ang-II. In the brain, AGT expression is localized mainly in astrocytes (glia) (7, 8) . To determine if locally synthesized AGT can be processed to Ang-II in the brain, we generated a transgenic mouse model expressing human AGT (hAGT) under the control of an astrocyte-specific (glial fibrillary acidic protein, GFAP) promoter (GFAP-hAGT) (9) . These mice exhibit hAGT expression primarily in the brain, but have a normal BP because of the strict species-specificity of the enzymatic reaction between AGT and renin (10) . Intracerebroventricular (ICV) injection of purified recombinant human renin (hREN) protein elicited a pressor response which was prevented by ICV pre-injection of an Ang-II type 1 (AT-1) receptor antagonist, losartan. Accordingly, we concluded that AGT synthesized in the brain can Morimoto et al. 6/18/2002 M2:04309 Revised be converted to Ang-II if renin is present. In addition to glia, AGT is expressed in select populations of neurons in regions of the brain, such as the subfornical organ (SFO) that can influence cardiovascular function (7, 11) . To determine the relevance of neuronal AGT, we also developed a transgene over-expressing hAGT from a neuronal promoter, synapsin-I (SYN) (12) .
As above, expression was high in the brain, and hAGT was exclusively localized in neurons coexpressing the neuronal marker NeuN. ICV infusion of purified hREN caused a transient pressor response suggesting that Ang-II release from either glial cells or neurons is functional in the brain.
ICV injection of homologous species renin increases BP in several animals (13, 14) , and early studies detected renin activity in the brain (15, 16) . Later, immunoreactive renin was found in the hypothalamus and cerebellar cortex in the mouse and rat brain, and in neurons in all areas of the human brain (17, 18) . Despite these observations and the clear documentation of the expression of the other RAS genes in the brain, the notion that renin is endogenously expressed in brain remains controversial. We recently reported hREN expression in the brain of a new transgenic model containing a tightly regulated hREN transgene (19) . Renin containing cells were detected in neurons in the brain stem, and glial cells in the hypothalamus and cortex. We therefore hypothesize that local synthesis of renin may cleave locally synthesized AGT to produce brain 
Analysis of Nucleic Acids:
Existence of transgene(s) was identified by PCR of tail genomic DNA using hREN-and/or hAGT-specific primer sets as described previously (25) . Results of PCR for GFAP-hREN and SYN-hREN founder mice were confirmed by Southern blot analysis. Tissues were harvested and snap-frozen in liquid nitrogen, and RNA was purified using TriReagent (Molecular Research Center Inc). RNase protection assays were performed using the RPA III kit (Ambion Inc., Austin, TX). Total RNA (50 µg) was hybridized to hREN and mouse β-actin probes labeled with [α-32 P]UTP by in vitro transcription and purified through a Sephadex G-50 spin column (Boehringer Mannheim). Protected fragments for hREN and mouse β-actin were 300 and 245 bp, respectively.
Plasma Renin Assay: Plasma renin activity (PRA) and concentration (PRC) were determined as described previously (26) . Radioimmunoassay was performed on plasma using the angiotensin-I (Ang-I) 125 I-labeled RIA kit (NEN Life Science Products Inc). Samples were diluted with reagent blank to remain on the linear portion of the standard curve. Chemicon International Inc); each incubation was at 25°C for 1 hour followed by rinsing with 0.1% Triton X-100 in PBS except for the last rinse which used PBS.
Physiology: Measurement of arterial pressure (AP) and heart rate (HR) and, ICV and intravenous (IV) infusion studies were performed in conscious, unrestrained mice as described previously (9) . Briefly, baseline AP and HR were measured continuously for 1 hour/day for 3 consecutive 
Results
GFAP-hREN and SYN-hREN transgenic mice were generated by fusing the GFAP and SYN promoters to a hREN cDNA. Since the mechanisms activating renin in the brain are unknown, we chose to use a hREN cDNA that was modified to contain a ubiquitous furin cleavage site in place of the prorenin converting enzyme site normally separating the prosegment from the active enzyme ( Figure 1A ). Three transgenic founders of each construct were identified; and two GFAP-hREN and three SYN-hREN founders were successfully bred to establish transgenic lines.
RNase protection assay was used to examine the tissue-specific expression of the transgenes. In Given the presence of "ectopic" hREN mRNA expression in tissues outside the brain, we were concerned that hREN protein might be released into the systemic circulation. Therefore, we measured plasma hREN concentration to determine if transgene expression outside the brain results in a significant increase of hREN protein in the systemic circulation ( Table 2 ). The
Morimoto et al. vs. 3.2±0.8 ng Ang-I/mL/hr, transgenic vs control) in the plasma of transgenic mice expressing hREN under the control of its own promoter (termed systemic-hREN transgenic mice) (27) .
Although all five lines of GFAP-hREN and SYN-hREN transgenic mice exhibited a slight increase in hREN concentration in the plasma, these values were not significantly different than in non-transgenic mice. Accordingly, it is unlikely that a significant amount of hREN protein is released into the systemic circulation in either the glial or neuronal transgenic models.
To examine the cell-specific expression of the transgene in the brain, double-labeling for hREN and GFAP (a glial marker) or MAP-2 or NeuN (neuronal markers) was performed. In GFAPhREN transgenic mice, hREN staining was observed in the cell bodies and processes of astrocytes in almost all regions of the brain as confirmed by co-staining with GFAP, but not with Table 3 ). In non-transgenic mice, some very light hREN immunostaining of glial-like elements was observed in cortex ( Figure 2E ). This immunostaining was generally distributed throughout the brain, and showed no regional specificity. The only exception to this was the SFO (Figure 2F -I) and area postrema (data not shown) where hREN co-localized with both GFAP and MAP-2. We showed previously that the GFAP promoter targeted expression of hAGT to neurons in the SFO (9) . In addition, hREN-positive radial astroglia were observed in cerebellum ( Figure 2J ). Strong non-specific staining was still detected in the Purkinje cell layer of the cerebellum in both controls and transgenic mice even though the antisera was preadsorbed Table 3 ). Only low background staining was observed in sections from non-transgenic controls ( Figure 3E ).
To examine the physiological significance of the local production of renin and AGT in the brain on BP and electrolyte homeostasis, we generated GFAP-hREN/GFAP-hAGT and SYNhREN/SYN-hAGT double transgenic mice. Because there is a strict species-specificity of the biochemical reaction between AGT and renin (10) Consequently, we examined effects of IV treatment with a ganglionic blocking agent, hexamethonium, and an AVP V 1 receptor antagonist, AVPX, on BP. IV injection of hexamethonium caused a greater fall in MAP in glial-specific mice than non-transgenic mice ( Figure 5B ). Although the reduction in MAP by IV AVPX tended to be greater in the transgenic mice, the difference did not achieve statistical significance ( Figure 5C ).
Finally, we measured drinking volume, salt preference, and urinary volume in both the glial-and neuronal-specific double transgenic mice ( Figure 6 ). Drinking volume and salt preference were significantly higher in both models compared with controls ( Figure 6A and 6B). Concomitant with increased water intake, urinary volume was significantly higher in the double transgenics ( Figure 6C ). Urinary osmolality was lower in glial-specific mice (1,612±163 mosmol/KgH 2 0, n=11) than controls (2,240±156 mosmol/KgH 2 0, n=11, P<0.01). Urinary osmolality tended to be lower in neuron-specific mice (1,804±168 mosmol/KgH 2 0, n=11) but did not reach statistical significance. In this light, urine output was lower in the neuron-specific mice than in the glialspecific mice ( Figure 6C ). Plasma osmolality was not different between the groups (glialspecific 335±9, n=5; neuron-specific 325±6, n=9; controls 316±7, n=6, in mosmol/KgH 2 0).
Morimoto et al. To examine the physiological role of brain-derived Ang-II in the regulation of BP, and to begin to distinguish between the effects of Ang-II derived from glial-cells and neurons we developed transgenic models expressing hAGT from the astrocyte-specific GFAP promoter and the neuronspecific SYN promoter (9, 12) . Double transgenic mice containing the GFAP-hAGT and an hREN transgene expressed systemically (in plasma, kidney, brain and other tissues), but not specifically in the brain resulted in hypertension (9) . Interestingly, double transgenic mice expressing SYN-hAGT and a systemically expressed hREN transgene were normotensive, despite the pressor response caused by infusion of purified hREN in the brain (12) . These studies allowed us to conclude that AGT synthesized in brain is the substrate for local synthesis of Ang-II. However, since hREN was present in the systemic circulation of that model and could potentially gain access to regions of the brain outside the blood-brain interface, e.g. the circumventricular organs (CVOs), we could not conclude that the Ang-II was derived from cleavage of AGT from brain-derived renin.
In order to generate a model of exclusive synthesis of Ang-II in the brain, we generated two additional transgenic models, expressing hREN under the control of the GFAP and SYN promoters. As shown herein, hREN mRNA was expressed in the brain, and hREN protein was Consequently, our data is consistent with the notion that Ang-II, chronically overproduced via processing of brain hAGT by brain hREN and ACE, stimulated local AT-1 receptors to raise BP.
In addition to the rise in BP, both double transgenic mice exhibited increased drinking volume and salt preference, suggesting that chronic overexpression of renin and AGT within the brain is capable of affecting water intake and salt appetite. Angiotensin-induced thirst is primarily mediated in the OVLT, SFO, and median preoptic nucleus and angiotensin-induced sodium (2, 38, 39) . It is tempting to speculate that increased concentration of Ang-II in these areas may be involved in the mechanism of altered behavior in these mice.
Mechanistically, the rise in BP in the glial-specific model may be due, at least in part, to an increase in sympathetic nerve activity (SNA). This is suggested by the greater fall in BP in double transgenic mice than control mice treated with hexamethonium. However, there was no significant difference in the reduction in BP in double transgenic and control mice treated with an AVP receptor antagonist. This differs from previous studies of double transgenic mice containing systemically expressed transgenes (R+/A+) where BP was significantly lowered by AVP receptor antagonist (33) . These data suggest that the mechanisms maintaining elevated BP in the models may differ. It is possible that AVP release, and therefore the response to AVP receptor antagonists is blunted in the GR/GA model due to feedback inhibition caused by the elevated drinking. In the glial-specific model, two separate mechanisms may be operating to maintain an elevation in BP, increased sympathetic outflow and increased water intake, caused by the activation of AT-1 receptors from local over-production of Ang-II in distinct nuclei regulating each process.
This raises an important question regarding the physiological relevance of these transgenic models. In the GFAP-hAGT model, hAGT is widely expressed in glial cells throughout the brain, thus emulating the normal pattern of astrocytic expression of AGT in brain (8) . With renin, however, we must recognize that hREN expression in the GFAP-hREN and SYN-hREN 
